GN
GNCP.US Gncc Capital Inc.
- Market cap
- USD 6.21M
- P/E
- -
- P/B
- -
- ROE
- -34.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Dec 2021.
Is GNCP.US undervalued?
Graham numberThe Graham number of Gncc Capital Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Gncc Capital Inc. fundamental analysis
No fundamental analysis for Gncc Capital Inc. yet.
Gncc Capital Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Gncc Capital Inc.
GNCC Capital, Inc. through its subsidiary, BioCann Pharma S.A.S., produces and sells cannabis CBD pharmaceutical grade oils. It sells its products through distribution channels in Colombia and throughout Latin America. The company is based in Las Vegas, Nevada.
Full company profileGncc Capital Inc. financial statements
2021 annualized: Fiscal year 2021 is not finished. Income statement and cash flow are annualized from 1 quarter up to Dec 31, 2021, the balance sheet is the latest quarter. Figures change when the annual report is published.
Gncc Capital Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2011 | 2012 | 2013 | 2014 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2021 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 36.4M | - | - | - | 6.13K | - | - | - |
| Gross Profit | 0.00 | 0.00 | 0.00 | 36.4M | - | - | - | 6.13K | - | - | - |
| Operating Income | -2.15M | -363K | -10.7M | -10.2M | -655K | -675K | -650K | -1.11M | -595K | -555K | -1.83M |
| EBITDA | - | - | - | - | -655K | -675K | -650K | -1.11M | -595K | -555K | -1.83M |
| Net Income | -2.98M | -1.32M | -11.9M | -12.2M | -4.20M | -4.08M | -4.06M | -3.55M | -595K | -555K | -1.83M |
| EPS | - | - | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Balance Sheet | |||||||||||
| Total Assets | 39.6K | 423K | 413K | 2.64M | 2.19M | 2.18M | 2.23M | 3.62M | 3.59M | 3.59M | 4.40M |
| Total Liabilities | 17.8M | 19.5M | 31.3M | 21.5M | 11.7M | 15.6M | 16.1M | 4.64M | 4.02M | 4.33M | 940K |
| Shareholders' Equity | -17.8M | -19.1M | -30.9M | -18.9M | -9.52M | -13.4M | -13.9M | -1.02M | -425K | -735K | 5.34M |
| Cash & Short-term Investments | 0.00 | 0.00 | - | - | 1.35M | 1.35M | 1.35M | 1.38M | 1.35M | 1.35M | 1.35M |
| Total Debt | - | - | - | - | 4.82M | 5.32M | 2.43M | 4.64M | 4.02M | 4.32M | 940K |
| Cash Flow | |||||||||||
| Operating Cash Flow | 0.00 | 0.00 | - | - | - | - | - | - | - | - | - |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | - | - | - | - | - | - | 0.00 |
| Ratios | |||||||||||
| ROE | - | - | - | - | - | - | - | - | - | - | -34.3% |
| ROA | -7,534.2% | -311.6% | -2,889.2% | -462.5% | -191.6% | -187.2% | -182.2% | -98.0% | -16.6% | -15.5% | -41.6% |
| Net Profit Margin | - | - | - | -33.4% | - | - | - | -57,928.1% | - | - | - |
| Debt to Equity | - | - | - | - | - | - | - | - | - | - | 0.18x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Gncc Capital Inc. dividends
Gncc Capital Inc. has not paid dividends in the last 6 fiscal years.
Last stock split: 1:15 on Dec 11, 2008.
Who owns Gncc Capital Inc.
Ownership data of Gncc Capital Inc. is not available yet.
Gncc Capital Inc. company profile
- Company name
- Gncc Capital Inc.
- Ticker
- GNCP.US
- Exchange
- USA Stocks
- Sector
- Basic Materials
- Industry
- Metals & Mining
- Fiscal year end
- September
- Address
- 848 North Rainbow Boulevard, Las Vegas, NV, United States, 89107
- Phone
- 702 990 0156
- Website
- gncc-capital.com
About Gncc Capital Inc.
GNCC Capital, Inc. through its subsidiary, BioCann Pharma S.A.S., produces and sells cannabis CBD pharmaceutical grade oils. It sells its products through distribution channels in Colombia and throughout Latin America. The company is based in Las Vegas, Nevada.
Gncc Capital Inc. management
2- Mr. Ronald Yadin LowenthalExecutive Chairman · born 1948
- Mr. Nicolaas Edward BlomCEO, President, CFO, Secretary & Director · born 1959